Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
about
Optimal primary surgical treatment for advanced epithelial ovarian cancerInterventions for the treatment of borderline ovarian tumoursNeoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma.Chemotherapy of ovarian cancer in elderly patientsBetter therapeutic trials in ovarian cancer.Integrated genomic analyses of ovarian carcinomaPaclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentLong-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group studyThe prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosisContinuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerIntensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group.Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancerEffect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerIn vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian CancerEfficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).Ovarian cancer (advanced)Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.Clinical trials and progress with paclitaxel in ovarian cancerSilencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.Mucinous tumors of the ovary: current thoughts on diagnosis and managementUnmasking the complexities of mucinous ovarian carcinoma.Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivoFirst-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report.Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancerAbagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.Primary ovarian cancer chemotherapy: current standards of careResistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.Molecular approaches to personalizing management of ovarian cancer.
P2860
Q24234923-333903DB-75B2-4A66-81C9-2881D96C06D6Q24235347-E3994433-5255-4BF8-B3DF-FC113EA47223Q24817101-FEA7B9E8-7D06-4442-B34B-5FD8D343F400Q26771397-9E624ED4-B745-447C-94EE-3538A578FB88Q27691432-9100EE5D-3240-42B5-9055-8EDFCEC8A31EQ27860518-D6A4B23F-C4EF-4F66-A012-2C0169D32135Q28073057-93F23CC5-C290-419D-BAD7-8F4AA8F9E5F7Q30359356-1839622D-58CF-4285-A606-37B4B7AB412BQ30405874-0C1F3E20-1775-44F8-8671-0B9EAFD86D47Q30436714-A773EE70-6031-4463-90E5-3CEEECFC4850Q30438803-3541B8F9-DED4-4E05-95F7-EF69F8E8EDBFQ30717971-7CFBB47B-A169-4F92-B91E-41DD022E842BQ31011575-AC04ADB2-9D38-4886-A7BE-F0448AC31541Q33315395-E09654C1-C8C8-4D0F-9454-17DAF731F069Q33317044-971FDA7A-35B8-499B-80F3-793637189E36Q33366785-24C3B579-DA0A-4C11-8715-BF46D7D27B22Q33376938-4D985BC8-F1BA-4448-B00D-BC810996CD78Q33386456-D2AF74E1-05A2-4891-97FC-19055C5EBA51Q33397995-DA56C2DF-2469-4F28-B90A-2C5ACF897AF8Q33553873-0BC8B9E9-B047-4332-B3CB-F0CED0B2B8A1Q33718820-57D29D4D-2FA7-489D-A7DE-B40667FAB4A7Q33756409-BF6EA0C5-3A17-43D1-B4EC-97B598C50590Q33813161-453701DD-82A6-430B-9825-D2B4AF837B98Q33880468-841C8041-409F-4896-AC89-DB7B98E27F3CQ33953209-1A3DEB99-DCF6-47F4-969F-16947F8A72F1Q34010642-19A475BF-7381-419B-A0F5-6ED96BA58CC4Q34069349-344D0BB2-E77D-43C8-A9CD-AC9AAAD48827Q34510070-20B17E65-DEC9-4408-A6E8-7A27346E005AQ34550420-B2DDFC91-FA51-4148-B85F-D1D65057CBD7Q34667838-428DDA2F-51E4-4926-B963-B628CE704260Q34695404-D1690B29-0314-4D70-B948-C3B8ADA1CB11Q34814991-B7547164-DCEA-4896-AED5-79E4BC93F1F6Q34954738-E66BEB37-0927-4594-9B6D-355B8DF5BA2BQ35042000-ED2E8D39-7BF7-46C0-87C1-106A56952327Q35114915-10EE2403-F0ED-4CE5-9231-366321E16231Q35564007-28EAC64F-2515-4CDE-9D53-05E363C77342Q35602173-817CBC1D-33F7-475A-914B-075FD25410C1Q35602185-CD46512E-545C-411D-A53C-9BB252140BB4Q35695164-84A93024-11BD-4396-873F-52645736E473Q35760160-9FA08B6F-2D5B-4719-AC76-C819A3946159
P2860
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase III randomized study of ...... ecologic oncology group study.
@ast
Phase III randomized study of ...... ecologic oncology group study.
@en
Phase III randomized study of ...... ecologic oncology group study.
@nl
type
label
Phase III randomized study of ...... ecologic oncology group study.
@ast
Phase III randomized study of ...... ecologic oncology group study.
@en
Phase III randomized study of ...... ecologic oncology group study.
@nl
prefLabel
Phase III randomized study of ...... ecologic oncology group study.
@ast
Phase III randomized study of ...... ecologic oncology group study.
@en
Phase III randomized study of ...... ecologic oncology group study.
@nl
P2093
P1476
Phase III randomized study of ...... ecologic oncology group study.
@en
P2093
P R Kucera
R D Alvarez
T H Niemann
P304
P356
10.1200/JCO.2000.18.1.106
P407
P577
2000-01-01T00:00:00Z